Fetch.ai, Ocean Protocol and SingularityNET Unite to Create Artificial Superintelligence Alliance
SingularityNET (SNET), the world's first decentralized Artificial Intelligence (AI) network, Fetch.ai, a Web3 platform for the new AI economy, and Ocean Protocol, a decentralized data exchange platform to protect data, today announced the launch of the Artificial Superintelligence Alliance. The creation of the largest open-sourced, decentralized network through a multi-billion token merger is a major step that accelerates the race to Artificial General Intelligence (AGI).
The Alliance is the brainchild of three leading minds in decentralized AI. Dr. Ben Goertzel, renowned as the “Father of AGI”, founded SNET as a blockchain-based marketplace and framework for AI services. DeepMind founding investor Humayun Sheikh built Fetch.ai as a decentralized multi-agent platform to deploy and commercialize AI applications. Trent McConaghy, the architect of the AI-based software that most chip designers use to drive Moore’s Law, formed Ocean Protocol to provide a platform for data exchange and the seamless trade of tokenized data assets.
As part of the formation of the Alliance, the $FET, $OCEAN and $AGIX tokens that fuel the three Alliance member networks will be merged into a single $ASI token that will function across the combined decentralized AI network, providing unprecedented scale and power.
Built for Super Intelligence
“As the AI revolution intensifies it is imperative that AGI and ASI are not owned and controlled by any particular party with their own biased interests,” comments Dr. Ben Goertzel, CEO and Founder of SNET. “They should be rolled out in an open, democratic and decentralized way. This has been the joint vision of SNET, Fetch.ai and Ocean Protocol from their inception, and for this reason it makes total sense that our three projects come together to form a tokenomic network that has greater power to take on Big Tech and shift the center of gravity of the AI world into the decentralized ecosystem.”
“In a world of exponential AI innovation, the giants of Big Tech dominate the headlines and conversation,’” remarks Humayun Sheikh, Fetch.ai CEO & Founder. “We are forging a different path. Our mission with this token merger is to combine our platforms to ensure ethical and transparent AI that facilitates direct interactions between developers and users to bypass the traditional gatekeepers of centralized authorities. This enhances data privacy and paves the way for a more democratic and trustworthy AI ecosystem and encourages global participants to contribute.”
Compelling Strategic Rationale
- Catalyzed by Rise of AI and Growth of Three AI Projects: The combination is born of a period of unprecedented growth for the AI projects. The deal provides an unparalleled opportunity for these three influential leaders to create a powerful compelling alternative to Big Tech’s control over AI development, use and monetization.
- Creates a Decentralized AI Infrastructure at Scale: Decentralized AI leverages blockchain technology to turn AI systems, whose inner workings are hidden from the public, into open networks for coordinating machine intelligence towards shared objectives. The fusion of SNET, Fetch.ai and Ocean Protocol’s research, brands, technologies and products creates a foundation to build a scalable AI infrastructure which ensures ethical and trustworthy practices.
- Accelerates Investment into AGI: Goertzel, Sheikh and McConaghy have long been acolytes and early-adopters of Artificial Intelligence – all focused on making AGI a reality. This Superintelligence Alliance facilitates the commercialization of each foundation’s technology, and enables wide scale access to cutting-edge AI platforms and large databases. This groundbreaking move advances the path to AGI on the blockchain.
Transaction Details
Bruce Pon, Ocean Protocol CEO & Co-Founder, believes the combination can deliver on the promise of a vertically integrated stack of decentralized technologies with scale to compete globally. “The combination of our technologies creates a leader in R&D, applications and commercialization of AGI,” Pon notes. “The unified $ASI token is the glue to orchestrate all actors with common incentives. $ASI tokens are used to secure the public network, as data access tokens and to unlock computation without needing traditional banking and payment rails. It is the native currency for the machine economy.”
If the proposal receives majority approval from the respective communities, the following will occur:
- $FET will be rebranded as $ASI, with a total supply of 2.63055 billion tokens
- $AGIX tokens migrate to $ASI, at a conversion rate of 0.433350:1
- $OCEAN tokens migrate to $ASI, at a conversion rate of 0.433226:1
- If the FDV of all three tokens as of March 26, 2024 were carried over fully into $ASI, it would have a total combined FDV of $7.6 billion USD.
Leadership and Governance
Upon closing of this token merger, a governing council for the Artificial Superintelligence Alliance will form to monitor and guide operations of the newly merged tokenomic network. The Alliance will be led by Ben Goertzel, Humayun Sheikh, Bruce Pon and Trent McConaghy. The organizations that guide development of the three merging networks, Fetch.ai, Ocean Protocol Foundation and SNET Foundation, will continue to operate as separate entities, but will collaborate closely in the shared $ASI tokenomic ecosystem and in the operation of the Alliance.
“Among our many commercial and research goals for this combined network to work is to launch a decentralized neural-symbolic AGI system with globally-superior capabilities in key areas like logical and scientific reasoning and artistic creativity,” Goertzel continues. “The impact of such a system may greatly exceed what we’ve seen from significant LLMs and lead the global economy into a new era of beneficial decentralized AGI and ASI.”
About SingularityNET
SingularityNET was founded by Dr. Ben Goertzel with the mission of creating a decentralized, democratic, inclusive and beneficial Artificial General Intelligence (AGI). According to Dr. Goertzel, AGI should be independent of any central entity, open to anyone and not restricted to the narrow goals of a single corporation or even a single country. The SNET team includes seasoned engineers, scientists, researchers, entrepreneurs, and marketers. The core platform and AI teams are further complemented by specialized teams devoted to application areas such as finance, robotics, biomedical AI, media, arts and entertainment.
For additional information on SNET, visit: https://singularitynet.io/
About Fetch.ai
Fetch.ai, a Cambridge-based AI company, is redefining the possibilities of an intelligent and connected world through its AI agent-based technology. Fetch.ai's infrastructure technology enables developers and businesses to build, deploy & monetize through an agent-based modular platform for the new generation of AI applications. The company's core product, DeltaV, fuses Language Models (LLMs) and AI Agents to create an open and dynamic marketplace that connects users to services and reimagines the current search experience.
Learn more at www.fetch.ai and on X.
About Ocean Protocol
Ocean was founded to level the playing field for AI and data. Ocean tools enable businesses and individuals to trade tokenized data assets seamlessly to manage data all along the AI model life cycle. Ocean-powered apps include enterprise-grade data exchanges, data science competitions and data DAOs. The Ocean Predictoor product has over $800M in monthly volume six months after launch with a roadmap to scale foundation models globally.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327003765/en/
Contact information
Media Contact
FTI Consulting
Fetch.ai@fticonsulting.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
